Project Grant R21AI202047
Award Date 8/13/26
Completion Date 7/31/28
Dollars Obligated $265K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $256,074 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize and advance preclinical development of an immunotherapeutic targeting CD8 T cells for genital herpes caused by herpes simplex virus infection. The award funds research to boost the levels and localization of HSV-specific CD8 T cells, with the objective of achieving a functional cure for...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded $902,741 to the University of Washington on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds basic research into the cell type-specific regulation of STING signaling, a central pathway in innate immune response with implications for antiviral immunity, antitumor immunity, and aging-associated inflammation. The research investigates why STING activation produces...
- The National Institute of Allergy and Infectious Diseases awarded Washington State University $618,650 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on ZBP1 signaling in respiratory syncytial virus (RSV) triggered host defense and pathogenesis. The research examines how RSV activates the immune sensor protein ZBP1, which triggers necroptosis in infected stromal cells and pyroptosis in myeloid cells. The project investigates...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Emory University $100,228 on November 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into autoreactive, extrafollicular B cell pathways in a TLR7-driven murine model. The project addresses gaps in understanding the origins of extrafollicular effector B cells and the system-wide and microenvironmental signaling that...
- The National Institute of Allergy and Infectious Diseases awarded $264,750 to the University of Washington on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of three transcriptional regulators—DR1, DRAP1, and BTAF1—in suppressing interferon responses triggered by self-RNA ligands. The research characterizes how loss of these proteins induces robust interferon responses and explores the immunostimulatory double-stranded RNA...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Hospital $911,271 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms regulating integration of engineered B cells in intestinal immunity and inflammation. The research aims to develop a B cell-based immunotherapy platform for treatment of inflammatory bowel disease and related immune-mediated diseases. The project focuses on long-lived plasma...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $238,899 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct preclinical evaluation of human monoclonal antibodies for herpes simplex virus type 2 (HSV-2) therapeutics. The research isolates and characterizes antibody-secreting cells discovered in genital skin tissue up to four months following HSV lesion healing. The project involves comprehensive...
- The National Institute of Allergy and Infectious Diseases awarded Kaiser Foundation Hospitals $825,617 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate long-term effectiveness of recombinant zoster vaccine (RZV) against herpes zoster and postherpetic neuralgia. The award funds a longitudinal observational study assessing RZV effectiveness over time in real-world populations, addressing a gap in evidence where clinical trials have...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research to develop tools for marginal zone-specific gene expression manipulation in B cells. The project investigates how mature B cell subsets—follicular, marginal zone, and B-1 cells—contribute to protective immune responses in infection and pathogenic responses...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $804,183 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to design bifunctional chimeric proteins that redirect immune responses against antibiotic-resistant bacterial pathogens. The project applies deep learning-enabled protein design to create bacterial targeting chimeras (BacTACs) that simultaneously bind surface proteins on antibiotic-resistant bacteria...